Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 23andMe Holding Co. ME

Consumer Cyclical Healthcare Advertising Agencies
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including... see more

Recent & Breaking News (NDAQ:ME)

23andMe announces CEO's intention to pursue a potential take-private

GlobeNewswire 4 days ago

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

GlobeNewswire April 5, 2024

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

GlobeNewswire March 20, 2024

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago

GlobeNewswire March 19, 2024

23andMe Launches New Genetic Reports on Common Forms of Cancer

GlobeNewswire March 6, 2024

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

GlobeNewswire March 5, 2024

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

Accesswire February 27, 2024

23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users

Accesswire February 26, 2024

23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users

Accesswire February 22, 2024

23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data

Accesswire February 21, 2024

23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users

Accesswire February 20, 2024

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

Accesswire February 16, 2024

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

Accesswire February 15, 2024

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

Accesswire February 14, 2024

23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users

Accesswire February 13, 2024

Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach

Accesswire February 12, 2024

DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected

Accesswire February 9, 2024

DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected

Accesswire February 8, 2024

23andMe Reports Third Quarter Fiscal 2024 Financial Results

GlobeNewswire February 7, 2024

DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected

Accesswire February 7, 2024